Have a personal or library account? Click to login
The diagnostic value of lipoprotein-related phospholipase A2 and matrix metalloproteinase-9 in identifying patients with coronary plaque or stenosis Cover

The diagnostic value of lipoprotein-related phospholipase A2 and matrix metalloproteinase-9 in identifying patients with coronary plaque or stenosis

Open Access
|Aug 2025

References

  1. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC/AHA guidelines for coronary angiog raphy. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756-824. DOI: 10.1016/S0735-1097(99)00126-6
  2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011; 123: 18-209 DOI: 10.1161/CIR.0b013e3182009701
  3. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006; 56: 967-976.
  4. Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Importance of primary capture and L-selectindependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo. J Exp Med. 2001;194:205-18. DOI: 10.1084/jem.194.2.205
  5. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995;92:8264-8. DOI: 10.1073/pnas.92.18.8264
  6. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893-7. DOI: 10.1073/pnas.92.9.3893
  7. Chen L, Chester MR, Redwood S, Huang J, Leatham E, Kaski JC. Angiographic stenosis progression and coronary events in patients with ‘stabilized’ unstable angina. Circulation. 1995;91:2319-24 DOI: 10.1161/01.CIR.91.9.2319
  8. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276-82 DOI: 10.1056/NEJM199705013361802
  9. Fukuda D, Shimada K, Tanaka A, Kusuyama T, Yamashita H, Virmani R. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris.Am J Cardiol. 2006 Jan 15;97 (2):175-80. DOI: 10.1016/j.amjcard.2005.08.020
  10. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354: 1264-1272. DOI: 10.1056/NEJMoa054013
  11. Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010; Jun;56(6):967-76. DOI: 10.1373/clinchem.2009.137489
  12. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reative protein in the arterial intima: rol of C-reative protein receptor-dependent monocyte recruitment in atherogenenesis. Arterioscler Thromb Vase Biol. 2000; 20:2094-9. DOI: 10.1161/01.ATV.20.9.2094
  13. Oei H-H S, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation. 2005;111:570-575. DOI: 10.1161/01.CIR.0000154553.12214.CD
  14. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degredation of platelet-activating factor. J Biol Chem. 1987;262:4215-4222. DOI: 10.1016/S0021-9258(18)61335-3
  15. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51: 2264-2273. DOI: 10.1373/clinchem.2005.058404
  16. Persson M, Nilsson J-A, Nelson JJ, Berglund G. The epidemiology of Lp-PLA2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007;190:388-396 DOI: 10.1016/j.atherosclerosis.2006.02.016
  17. Budoff MJ, Achenbach S, Duerinckx A. Clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography. J Am Coll Cardiol. 2003; 42:1867-78. DOI: 10.1016/j.jacc.2003.07.018
  18. Achenbach S, Ropers D, Hoffmann U. Assessment of coronary remodeling in stenotic and nonstenotic coronary atherosclerotic lesions by multidetector spiral computed tomography. J Am Coll Cardiol. 2004; 43: 842-7. DOI: 10.1016/j.jacc.2003.09.053
  19. White CS, Kuo D. Chest pain in the emergency department: role of multidetector CT. Radiology. 2007; 245: 672-81. DOI: 10.1148/radiol.2453061481
  20. Schuijf JD, Jukema JW, van der Wall EE, Bax JJ. Multi-slice computed tomography in the evaluation of patients with acute chest pain. Acute Card Care. 2007; 9: 214-21. DOI: 10.1080/17482940701589275
  21. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138 (52): 19-20. DOI: 10.1016/S0002-8703(99)70266-8
  22. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the framingham score : ımplications for future risk assessment: results from a large cohort study in Southern Germany. Circulation. 2004;109:1349-1353. DOI: 10.1161/01.CIR.0000120707.98922.E3
  23. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26:2523-2529. DOI: 10.1161/01.ATV.0000244681.72738.bc
  24. Schoenhagen P, McErlean ES, Nissen SE. The vulnerable coronary plaque. J Cardiovasc Nurs. 2000 Oct;15(1):1-12. DOI: 10.1097/00005082-200010000-00002
  25. Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M, et al. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery diseaseJ Atheroscler Thromb. 2014;21 (8):755-67. DOI: 10.5551/jat.23465
  26. Kunutsor SK, Zaccardi F, Karppi J, Kurl S, Laukkanen JA. Is High Serum LDL/HDL Cholesterol Ratio an Emerging Risk Factor for Sudden Cardiac Death. Findings from the KIHD Study J Atheroscler Thromb. 2017 Jun 1;24 (6):600-608. DOI: 10.5551/jat.37184
  27. Moriyama K, Takahashi E. Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDLCholesterol in Japanese Subjects with TG Levels <400 mg/dL. J Atheroscler Thromb. 2016 Sep 1;23 (9):1126-37. DOI: 10.5551/jat.33985
  28. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein-associated phospholipase A (2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.Arterioscler Thromb Vasc Biol. 2008 Jun;28 (6):1172-8. DOI: 10.1161/ATVBAHA.107.160739
  29. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101:51-50. DOI: 10.1016/j.amjcard.2008.04.018
  30. Lerman A, McConnell JP. Lipoprotein-associated phospholipase A2: A risk marker or a risk factor? Am J Cardiol. 2008;101:11-22. DOI: 10.1016/j.amjcard.2008.04.014
  31. Ferri N, Paoletti R, Corsini A. Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers. 2005 Jul-Aug;10 (4):219-37. DOI: 10.1080/13547500500216660
  32. Segers D, Helderman F, Cheng C, van Damme LC, Tempel D, Boersma E, et al. Gelatinolytic activity in atherosclerotic plaques is highly localized and is associated with both macrophages and smooth muscle cells in vivo. Circulation. 2007;115:609-16. DOI: 10.1161/CIRCULATIONAHA.106.636415
  33. Chen Y, Fu Y, Wang S, Chen P, Pei Y, Zhang J, et al. Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged ≥ 65 years. Cardiovasc Diabetol. 2022 Nov 17;21(1):252. DOI: 10.1186/s12933-022-01668-5
  34. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511. DOI: 10.1161/01.CIR.0000052939.59093.45
  35. Liu H, Yao Y, Wang Y, Ji L, Zhu K, Hu H. Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study. J Cell Mol Med. 2018 Oct;22(10):5145-5150. DOI: 10.1111/jcmm.13803
  36. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta. 2006; 1761: 1246-59 DOI: 10.1016/j.bbalip.2006.07.011
  37. Daniels LB, Laughlin GA, Mark J, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein -associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apperently healthy older populatıon: the Rancho Bernardo study. J Am Coll Cardiol. 2008; 51: 913-919. DOI: 10.1016/j.jacc.2007.10.048
  38. Hyemoon C, Hyuck Moon K, Jong-Youn K, Young Won Y, Rhee J, Choi EY, et al.Lipoprotein-Associated Phospholipase A2 Is Related to Plaque Stability and Is a Potential Biomarker for Acute Coronary Syndrome. Yonsei Med J 55(6):1507-1515, 2014. DOI: 10.3349/ymj.2014.55.6.1507
  39. Maiolino G, Bisogni V, Rossitto G, Rossi GP. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.World J Cardiol. 2015 Oct 26;7 (10):609-20. DOI: 10.4330/wjc.v7.i10.609
  40. Tooran A, Soudabeh F, Toktam Kazemi F, Reza F, Rahim R, Movahedi M, et al. Evaluation of MMP-9, IL-6, TNF-α levels and peripheral blood mononuclear cells genes expression of MMP-9 and TIMP-1 in Iranian patients with coronary artery disease. Cardiovasc Thorac Res. 2023, 15(4), 223-230. DOI: 10.34172/jcvtr.2023.31844
  41. Liu B, Su L, Loo SJ, Gao Y, Khin E, Kong X, et al. Matrix metallopeptidase 9 contributes to the beginning of plaque and is a potential biomarker for the early identification of atherosclerosis in asymptomatic patients with diabetes. Front Endocrinol (Lausanne). 2024 Apr 10;15:1369369. DOI: 10.3389/fendo.2024.1369369.
DOI: https://doi.org/10.2478/rrlm-2025-0015 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 143 - 150
Submitted on: Apr 16, 2025
Accepted on: May 10, 2025
Published on: Aug 6, 2025
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Neslihan Sungur, Sabahattin Muhtaroğlu, Didem Barlak Keti, Hakan Imamoğlu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.